View Document Preview and Link Document Date: 2015-04-01 19:02:34 Open Document File Size: 293,74 KB Share Result on Facebook
City WALTHAM / / Company Alere Inc. / / Country United States / / / Event FDA Phase / / IndustryTerm healthcare professionals / isothermal nucleic acid amplification technology / healthcare settings / healthcare providers / clinical and economic healthcare outcomes / / MedicalCondition non-invasive GAS infections / cardiometabolic disease / skin infection / Streptococcal (GAS) Disease / infected person's cough / influenza A / impetigo / invasive GAS infections / necrotizing fasciitis / superficial skin infections / streptococcal toxic shock syndrome / scarlet fever / GAS infections / Infectious Disease / Streptococcus infections / / MedicalTreatment antibiotics / / Organization U.S. Food and Drug Administration / FDA / / Person Jackie Lustig / Avi Pelossof / / / Position Global President / Director / Corporate Communications Jackie.Lustig@alere.com / physician / Vice President / Investor Relations ir@alere.com / Global President of Infectious Disease / / Product Alere i molecular platform / Alere i / Alere™ / / ProvinceOrState Massachusetts / / Technology isothermal nucleic acid amplification technology / diagnostic tests / / URL www.alere.com / http / SocialTag 
Alere Receives FDA Clearance for Alere™ i Strep A Rapid Molecular Test Newest testing application on innovative Alere i molecular diagnostic platform detects Group A Streptococcus infections in 8 minutes or less WALTHA